This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CAR-T therapy | |
|---|---|
| Name | CAR-T therapy |
| Caption | Chimeric antigen receptor T cell schematic |
| Specialty | Hematology, Oncology, Immunology |
| Invented by | Zelig Eshhar; Carl June |
| First use | 2010s |
CAR-T therapy is an adoptive cellular immunotherapy that uses genetically modified T lymphocytes to target malignancies. Developed through collaborations among researchers at institutions such as Weizmann Institute of Science, University of Pennsylvania, Fred Hutchinson Cancer Research Center, and companies like Novartis and Kite Pharma, the approach transformed treatment for selected acute lymphoblastic leukemia and diffuse large B-cell lymphoma patients. Clinical milestones included pivotal trials at National Cancer Institute and regulatory decisions by agencies such as the United States Food and Drug Administration and the European Medicines Agency.
Early conceptual roots trace to work on T cell receptor engineering at the Weizmann Institute of Science and chimeric antigen receptor design by researchers including Zelig Eshhar. Preclinical development proceeded at institutions like Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Research Center, with translational leadership by groups at the University of Pennsylvania including Carl June. Corporate partnerships with Novartis, Gilead Sciences, Kite Pharma, and Juno Therapeutics enabled phase I–III trials conducted under protocols sponsored by the National Institutes of Health and academic centers such as MD Anderson Cancer Center. High-profile patient stories in publications associated with The New England Journal of Medicine and presentations at meetings like the American Society of Clinical Oncology accelerated adoption and regulatory review.
Modified autologous or allogeneic T cells express chimeric antigen receptors that combine an antigen-binding domain derived from a monoclonal antibody with intracellular signaling domains from molecules studied at the Salk Institute and described in work from labs including James Allison's group (noting immune checkpoint context). The extracellular single-chain variable fragment targets antigens such as CD19 or BCMA expressed on malignant B cells and plasma cells, triggering activation cascades involving signaling motifs characterized in research from Cold Spring Harbor Laboratory and Harvard Medical School. Co-stimulatory domains typically derive from costimulatory molecules first defined in studies at Dana-Farber Cancer Institute and include sequences from CD28 or 4-1BB, influencing expansion and persistence observed in trials at Fred Hutchinson Cancer Research Center and reported in journals like Nature Medicine.
Approved indications emerged from randomized and single-arm studies led by consortia including European Society for Medical Oncology centers and US cooperative groups. Indications include relapsed or refractory acute lymphoblastic leukemia in pediatric and young adult populations evaluated at Children's Hospital of Philadelphia and refractory diffuse large B-cell lymphoma cohorts treated at Memorial Sloan Kettering Cancer Center. Investigational uses span multiple myeloma targeting BCMA in programs from Bristol Myers Squibb and Bluebird Bio, and solid tumor programs explored at MD Anderson Cancer Center, Dana-Farber Cancer Institute, and University of California, San Francisco. Trials are registered through initiatives coordinated with the National Cancer Institute and reported at forums such as the European Hematology Association.
Manufacturing workflows developed in partnerships between academic GMP facilities at University of Pennsylvania and commercial sites for Novartis and Kite Pharma encompass leukapheresis, viral vector transduction (often lentiviral vectors characterized by work at Roche and Genentech), ex vivo expansion in bioreactors informed by engineering groups at Massachusetts Institute of Technology, and cryopreservation. Centralized and decentralized models emerged in networks including Mayo Clinic and Cleveland Clinic. Administration typically follows lymphodepleting chemotherapy regimens such as cyclophosphamide and fludarabine used in trials conducted at Stanford University, with inpatient monitoring protocols adapted from Johns Hopkins Hospital and outpatient transitions evaluated in pilot programs at Mount Sinai Health System.
Acute toxicities include cytokine release syndrome characterized in case series from University of Pennsylvania and neurologic toxicities termed immune effector cell–associated neurotoxicity syndrome described in reports from Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center. Management algorithms reference therapeutics such as tocilizumab (anti-IL-6 receptor) and corticosteroids deployed per guidance influenced by consensus statements from organizations like the American Society for Transplantation and Cellular Therapy. Long-term adverse effects include B cell aplasia documented in follow-up cohorts at MD Anderson Cancer Center and insertional oncogenesis risks monitored in registries coordinated with the Food and Drug Administration and European Medicines Agency.
Regulatory approvals began with biologics license applications reviewed by the United States Food and Drug Administration and marketing authorizations by the European Medicines Agency, leading to licensed products commercialized by Novartis (axicabtagene ciloleucel analogs licensed by partners) and Gilead Sciences (via Kite Pharma acquisitions). Reimbursement pathways involve national payers such as the Centers for Medicare & Medicaid Services in the United States and health technology assessment bodies like the National Institute for Health and Care Excellence in the United Kingdom. High per-patient costs prompted pricing debates involving stakeholders including PhRMA and policy discussions in venues such as the World Health Organization.
Current research programs at institutions including Broad Institute, Karolinska Institutet, European Molecular Biology Laboratory, and industry labs at Roche and Bristol Myers Squibb pursue enhancements: universal allogeneic products from companies like Allogene Therapeutics, armored CAR constructs combining cytokine modules investigated at Cold Spring Harbor Laboratory, dual-targeting receptors studied in consortia with Genentech, and non-viral gene delivery techniques developed at Salk Institute and MIT. Combinatorial strategies with immune checkpoint inhibitors inspired by University of Texas MD Anderson Cancer Center studies and synthetic biology platforms advanced at Harvard University aim to extend efficacy into solid tumors highlighted in programs at UCSF and Memorial Sloan Kettering Cancer Center. Longitudinal registries coordinated by the National Cancer Institute and multinational collaborations such as the International Society for Cell & Gene Therapy track outcomes, safety, and cost-effectiveness to guide future clinical practice.
Category:Immunotherapy